The data was announced during the 2025 North American Menopause Society (NAMS) Annual Meeting. Image credit: shisu_ka / Shutterstock.com. Entera Bio’s osteoporosis candidate for postmenopausal women ...
Inhibrx’s DR5-targeting antibody has more than doubled PFS compared with placebo in a Phase II trial in chondrosarcoma, a rare bone cancer with no approved targeted therapies. Image credit: Kateryna ...
While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...
Electra is assessing ELA026 for haematologic cancers, following promising initial clinical data. Credit: Motortion Films / Shutterstock.com. Electra Therapeutics has raised $183m in an oversubscribed ...
Neuphoria Therapeutics’ lead candidate, BNC210, has failed to show efficacy in the Phase III AFFIRM-1 trial in social anxiety disorder. Image credit: Blueastro via Shutterstock.com. Neuphoria ...
At CTS Nordics, Arnaud Dourlens explained how Sanofi has engaged between clinical operations and supply teams earlier to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback